Author Correction: EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma (Nature Communications, (2015), 6, 1, (8494), 10.1038/ncomms9494);EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Liu, Haiou ^a   Liu, Yidong ^a   Liu, Weisi ^a   Zhang, Weijuan ^a   Xu, Jiejie ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MICRORNA; MICRORNA 622; NEUTRALIZING ANTIBODY; PLERIXAFOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CXCR4 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HISTONE; MIRN622 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ANTIBODY; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; METHYLATION; MOLECULAR ANALYSIS; NEUTRALIZATION; TUMOR;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE OVEREXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VOLUME; UPREGULATION; ADOLESCENT; ADULT; AGED; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PROGNOSIS; TUMOR CELL LINE; TUMOR INVASION; YOUNG ADULT;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; AGED; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HISTONES; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RECEPTORS, CXCR4; YOUNG ADULT;

EID: 84942566555     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-021-26555-7     Document Type: Erratum

References (44)

1. Zlotnik, A. New insights on the role of CXCR4 in cancer metastasis. J. Pathol. 215, 211-213 (2008).
2. Jung, M. J. et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32, 209-221 (2013).
3. Domanska, U. M. et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur. J. Cancer 49, 219-230 (2013).
4. Mo, W. et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 152, 1077-1090 (2013).
5. Ghanem, I. et al. Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am. J. Transl. Res. 6, 340-352 (2014).
6. Xiang, Z. L. et al. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 9, 176 (2009).
7. Liu, H. et al. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell. Mol. Immunol. 5, 373-378 (2008).
8. Xiang, Z. et al. Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J. 15, 519-525 (2009).
9. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
10. Calin, G. A., Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866 (2006).
11. Han, Z. et al. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis 33, 131-139 (2012).
12. Schultz, N. A. et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod. Pathol. 25, 1609-1622 (2012).
13. Xie, J. et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol. Rep. 31, 1715-1722 (2014).
14. Meng, F. et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007).
15. Datta, J. et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68, 5049-5058 (2008).
16. Au, S. L. et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 56, 622-631 (2012).
17. Ladeiro, Y. et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47, 1955-1963 (2008).
18. Lazennec, G., Richmond, A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 16, 133-144 (2010).
19. Kryczek, I., Wei, S., Keller, E., Liu, R., Zou, W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am. J. Physiol. Cell Physiol. 292, C987-C995 (2007).
20. Li, W., Gomez, E., Zhang, Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 26, 527-533 (2007).
21. Righi, E. et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 71, 5522-5534 (2011).
22. Matsusue, R. et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann. Surg. Oncol. 16, 2645-2653 (2009).
23. Ma, W. F. et al. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis. Mol. Cancer Res. 7, 1613-1621 (2009).
24. Chen, Y. et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59, 1435-1447 (2014).
25. Peled, A., Wald, O., Burger, J. Development of novel CXCR4-based therapeutics. Expert Opin. Investig. Drugs 21, 341-353 (2012).
26. Schimanski, C. C. et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br. J. Cancer 95, 210-217 (2006).
27. Sutton, A. et al. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol. Cancer Res. 5, 21-33 (2007).
28. Zagzag, D. et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65, 6178-6188 (2005).
29. Planken, P. Microscopy: a terahertz nanoscope. Nature 456, 454-455 (2008).
30. Trabucchi, M. et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 459, 1010-1014 (2009).
31. Simon, J. A., Kingston, R. E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 10, 697-708 (2009).
32. Gao, S. B. et al. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma. Mol. Cancer Res. 12, 1388-1397 (2014).
33. Xu, L. et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J. Hepatol. 60, 590-598 (2014).
34. Wang, L. et al. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 59, 1850-1863 (2014).
35. Wong, C. C. et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140, 322-331 (2011).
36. Malarkey, D. E., Johnson, K., Ryan, L., Boorman, G., Maronpot, R. R. New insights into functional aspects of liver morphology. Toxicol. Pathol. 33, 27-34 (2005).
37. Shah, S. A. et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141, 330-339 (2007).
38. Imamura, H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38, 200-207 (2003).
39. Wang, S. et al. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. Cancer Sci. 104, 750-759 (2013).
40. Ryu, S. et al. Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell 23, 63-76 (2013).
41. Fu, Q. et al. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci. 105, 1427-1434 (2014).
42. Detre, S., Saclani Jotti, G., Dowsett, M. A. "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48, 876-878 (1995).
43. Balabanian, K. et al. CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4\+ T lymphocytes. J. Immunol. 173, 7150-7160 (2004).
44. Chien, C. H. et al. Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data. Nucleic Acids Res. 39, 9345-9356 (2011).